NASH

[Oncodesign] Oncodesign and TiumBio have announced the signature of a research collaboration agreement on R&D of potential drug candidates for fibrosis. Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis.

[Seal Rock Therapeutics, Inc.] Seal Rock Therapeutics, Inc. announced completion of the single ascending dose portion of its Phase I clinical trial of SRT-015, a next-generation, liver-selective inhibitor of Apoptosis Signal-regulating Kinase 1 for non-alcoholic steatohepatitis (NASH) and other liver diseases such as alcoholic hepatitis.

[Scientific Reports] Lesogaberan’s potential efficacy in non-alcoholic steatohepatitis (NASH) was tested in human stellate cells, human precision cut liver slices, and in vivo in a well-validated murine model of NASH.

[Science Translational Medicine] To identify a protease signature of nonalcoholic steatohepatitis (NASH), transcriptomic analysis of 355 human liver biopsies identified a 13-protease panel that discriminated clinically relevant NASH ≥F2 fibrosis from F0-F1 with high classification accuracy across two independent patient datasets.

[Biomedicine & Pharmacotherapy] The authors describe the mechanism of the succinate–GPR91 signaling pathway in NASH and summarize the drugs that act on this pathway, with the aim of providing a new approach to NASH treatment.

[Science Translational Medicine] Investigators used multiomics analysis of human cirrhotic liver, a Western diet – and carbon tetrachloride – induced minipig nonalcoholic steatohepatitis model, and genetically modified mice to unravel the landscape of the vascular adaptome at the single-cell level, in which endothelial cells and TH17 cells jointly contributed to liver cirrhosis.